India’s pharma sector is continuously making records. According to the information, till February in this financial year, Indian pharmaceutical exports stood at about $29 billion i.e. Rs 2.7 lakh crore, which shows an increase of five percent as compared to the same period last year. Director General of Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) K. Raja Bhanu said that this sector, whose current value is about $60 billion, is expected to grow to $130 billion by 2030.
How much was the export?
He said that despite global challenges, pharmaceutical exports have been one of the few sectors that has maintained its growth momentum. Pharmaceutical exports during the April-February period of FY 2026 stood at $ 28.29 billion, which shows an increase of 5.6 percent compared to the same period of FY 25. Formulations, biologicals, vaccines and AYUSH products mainly contributed to this growth. The official further said that exports reached $30.47 billion in the financial year 2024-25, which shows a growth of 9.4 percent on a year-on-year basis despite global price pressures and trade fluctuations.
Figures looked like this in February
If we talk about the report of market research firm Pharmarack, then in February this year, the Indian Pharmaceutical Market (IPM) grew by 11 percent, in which a good growth was seen in terms of value in the main therapies. Of these, anti-diabetic, cardiac and anti-infective therapies witnessed healthy growth of 15.5 per cent, 14.8 per cent and 7.6 per cent respectively, boosting the overall IPM growth. Sheetal Sapele, Vice-President (Commercial), Pharmarack, said that key therapies saw good growth in all three key growth drivers – introduction of new products, price and volume.
He further said that due to demand, good growth is being seen in the market, and in the last two-three months, IPM is also registering good growth in terms of volume. Between March 2025 and February 2026, IPM’s moving annual turnover (MAT, i.e. turnover for the last 12 months) increased by 8.4 percent, taking the total turnover to more than Rs 2.44 lakh crore, while unit sales in the domestic market increased by 0.7 percent.